When SaaS becomes fast fashion

Cerillion

Sam Altman recently floated the idea that software is entering a “fast fashion era” of SaaS. In one terse message, he challenged a core assumption of enterprise software: that durability, stability, and long‑term support are non-negotiable pillars. The implied wager is that speed, flexibility, and iteration will matter more.

At its core, Altman’s metaphor draws from fashion: low-cost items churned rapidly through trends, often with compromised quality or durability. In the SaaS context, that suggests a future where applications are spun up fast, iterated obsessively, and discarded nearly as fast, rather than being built for decades of operation. The danger, of course, is that many tools become disposable, losing institutional trust, fragmenting data, or creating churn in vendor relationships.

What’s accelerating all this is AI. Tools that generate code, assist in UI building, or stitch together backend services have lowered the technical barrier to launching a SaaS product. The “vibe coding” concept popularised by Andrej Karpathy hints at letting generative tools steer the creative process, a kind of codified intuition divorced from deep engineering. As more creators lean into such tools, we risk saturation: dozens of apps that do the same basic thing, with little to distinguish them beyond branding or minor features.

Cerillion plc (LON:CER) is a leading provider of billing, charging and customer management systems with more than 20 years’ experience delivering its solutions across a broad range of industries including the telecommunications, finance, utilities and transportation sectors.

Share on:

Latest Company News

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

SIRT6 positions Genflow Biosciences in a high-value area of longevity research

Genflow Biosciences is targeting SIRT6 as a potential route to improve DNA repair, metabolic control and healthier ageing.

Biotech Growth Trust portfolio company AtaiBeckley to be acquired by Eli Lilly

Eli Lilly’s proposed acquisition of AtaiBeckley values the biotechnology company at up to $3.8 billion, including contingent milestone payments. The transaction is the latest in a series of portfolio acquisitions contributing to BIOG’s performance.

Bridgepoint reports record first-half results as EBITDA rises 78%

Bridgepoint reported higher first-half earnings, record capital returns to fund investors and continued fundraising progress towards its updated target.

Burberry Group reports first-quarter growth across all major product categories

Burberry Group Plc said first-quarter FY2027 comparable retail sales rose 5%, driven by strong performance in the Americas and Greater China and growth across women’s, men’s, accessories and children’s divisions. The luxury brand highlighted momentum in outerwear, scarves and e-commerce, along with rising new customer acquisition and improved wholesale guidance for the first half.

RM Plc Assessment Pipeline Doubles as RM Ava Opens New Growth Markets (video)

RM Plc CFO Simon Goodwin explains why the Assessment pipeline has doubled, how RM Ava could unlock new professional and government-regulated testing markets, and where further efficiencies will come from after £20 million of annualised savings.

    Search